Tumor-related inflammation is indicated by elevated levels of inflammatory markers (e.g., C-reactive protein, CRP; interleukin 6, IL-6) and has been linked to poor outcomes in a number of malignancies, including lung cancer [5]. This evidence concerns the gene IL6 and lung carcinoma.